Fig. 5
From: The chromatin guardian ATRX is a strong prognostic biomarker in melanoma
ATRX (A–D) and CD34 (E–F) staining, 40× magnification, absence of staining (A, GIS-Score 0), moderate positivity in 11–50% of tumor cells (B, GIS-Score 4), moderate positivity in 51–90% of tumor cells (C, GIS-Score 6), moderate positivity in > 90% of tumor cells (D, GIS-Score 8); low vessel density (E, < 20), high vessel density (F, ≥ 20).
